MFDS to Narrow Efficacy and Effect Range of Chongkundang's 'Emoten Capsule'
Scheduled to change to 'Relief of Knee Osteoarthritis Symptoms'
[Asia Economy Reporter Kim Ji-hee] The Ministry of Food and Drug Safety announced on the 21st that it plans to change the indications and usage of 'Emotencapsule,' manufactured by Chong Kun Dang, from osteoarthritis (degenerative osteoarthritis) and adjunctive therapy for bleeding and pain caused by periodontal disease (alveolar abscess) to 'symptom relief of adult knee osteoarthritis.'
This measure follows the change in the indications and usage of the product in France, the original development country of Emotencapsule, to 'symptom relief of adult knee osteoarthritis.' The final approval change is expected to be completed in July after administrative procedures such as public consultation and prior notice.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
The Ministry of Food and Drug Safety requested medical professionals such as doctors and pharmacists to use alternative medicines for patients with bleeding and pain caused by periodontal disease (alveolar abscess) or osteoarthritis in parts other than the knee. It also asked patients currently taking Emotencapsule for these conditions to consult with medical professionals such as doctors and pharmacists regarding the use of alternative medicines.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
